Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Employees

277

Sector

Biotechnology & Medical Research

More about the company

21/02/24	AbbVie CEO to Retire; COO Robert Michael Named Successor	MT
13/02/24	BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	AN
13/02/24	Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	MT
13/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	CI
13/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	CI
13/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	CI
13/02/24	Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	MT
13/02/24	AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	MT
13/02/24	AbbVie: acquisition of ImmunoGen finalized
13/02/24	AbbVie Acquires ImmunoGen for $31.26 per Share	MT
12/02/24	Immunogen, Inc. Announces Board Changes	CI
12/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	CI
12/02/24	AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	CI

05/12/23	Piper Sandler Downgrades ImmunoGen to Neutral From Overweight, Raises Price Target to $31 From $24	MT
02/12/23	Barclays Downgrades ImmunoGen to Equalweight From Overweight, Raises Price Target to $31 From $27	MT
02/12/23	Deutsche Bank Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $25	MT
01/12/23	BMO Capital Downgrades ImmunoGen to Market Perform From Outperform, Price Target is $31	MT
01/12/23	Guggenheim Downgrades ImmunoGen to Neutral From Buy, Adjusts Price Target to $31 From $25	MT

12/02/24	AbbVie Completes Acquisition of ImmunoGen	PR
02/02/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/01/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
04/01/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11/12/23	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	BU

13/02/24	Diamondback Energy : Abbvie, Diamondback Energy, Gilead...les valeurs à suivre aujourd'hui à Wall Street
13/02/24	Abbvie : abaisse ses perspectives après le rachat d'Immunogen
13/02/24	AbbVie : acquisition d'ImmunoGen finalisée
03/02/24	Omzetdaling Abbvie valt mee
22/01/24	HBM bleibt nach neun Monaten in den roten Zahlen

Manager	Title	Age	Since
Stacy Coen PRN	Corporate Officer/Principal	55	03/06/2020
Theresa Wingrove CTO	Chief Tech/Sci/R&D Officer	68	24/01/2011

ImmunoGen, Inc. Stock

Stocks

IMGN

US45253H1014

Biotechnology & Medical Research

Latest news: ImmunoGen, Inc.

Analysts' recommendations: ImmunoGen, Inc.

Press Releases: ImmunoGen, Inc.

News in other languages: ImmunoGen, Inc.

Managers and Directors: ImmunoGen, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/24	Richard Wallace	Issuer sale	Director	354,013	0.1267%
12/2/24	Daniel Char	Issuer sale	General Counsel	423,825	0.1517%
12/2/24	Mark Enyedy	Issuer sale	CHIEF EXECUTIVE OFFICER; Director	5,071,495	1.8154%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOGEN, INC.	-.--%	+6.73%	-	-	8.36B
WUXI APPTEC CO., LTD.	+1.52%	-7.19%	+51.66%	+69.99%	65.83B
LONZA GROUP AG	+1.70%	+10.20%	+12.88%	+87.50%	51.87B
ARGENX SE	+6.93%	+7.85%	+6.16%	+70.97%	51.2B
IQVIA HOLDINGS INC.	+1.21%	+2.65%	+26.19%	+45.15%	43.76B
BEONE MEDICINES AG	+2.37%	+7.69%	+17.99%	+127.54%	42.09B
REVOLUTION MEDICINES, INC.	+6.79%	+2.33%	+257.04%	+589.45%	39.04B
CELLTRION, INC.	+2.16%	+9.87%	+18.92%	+59.70%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+4.98%	+30.53%	+25.63%	22.8B
Average	+2.60%	+4.08%	+51.53%	+120.54%	41.76B
Weighted average by Cap.	+2.78%	+3.76%	+49.84%	+122.34%